64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)

Phase 1/2 Terminated 4 enrolled Clarity Pharmaceuticals Ltd

NaSingle-groupOpen-labelTreatment

Summary

The aim for this study is to determine the safety and efficacy of 67Cu-SAR-BBN in participants with Gastrin Releasing Peptide Receptor (GRPR)-expressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA-617.

Timeline

Start: 2023-06-15
Primary completion: 2025-04-23
Completion: 2025-04-23

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision”

Publications

Taunk NK, Escorcia FE, Lewis JS, Bodei L. Radiopharmaceuticals for Cancer Diagnosis and Therapy: New Targets, New Therapies-Alpha-Emitters, Novel Targets. Cancer J. 2024 May-Jun 01;30(3):218-223. doi: 10.1097/PPO.0000000000000720.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	64Cu-SAR-BBN	Diagnostic / imaging agent	200 mbq	—
Subject	67Cu-SAR-BBN	Unknown	—	—